• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to a process for stereoselectively producing a compound of Formula A wherein Q, RA and RB and PG are as defined in the description and wherein the reaction takes place in the presence of a bis-quaternary cinchona alkaloid salt phase transfer catalyst.
    公开号:EP3680240A1
    申请号:EP20154142.2
    申请日:2013-03-13
    公开日:2020-07-15
    发明作者:Bangping Xiang；Nobuyoshi Yasuda
    申请人:Merck Sharp and Dohme Corp；
    IPC主号:C07D453-00
    专利说明:
    [0001] Cinchona alkaloid salts are known phase transfer catalysts useful in the asymmetric formation of carbon-carbon, carbon-heteroatom or carbon-halide bonds. See Takashi Ooi and Keiji Maruoka, Recent Advances in Asymmetric Phase-Transfer Catalysis, Angew. Chem. Int. Ed. 2007, 46, 4222-4266 ("Maruoka"). Maruoka reviews the various reactions in which phase-transfer catalysis is useful, including enantioselective alkylation, Michael addition, aldol and related reactions and Darzens reaction. Maruoka at page 4223 discusses the advantages of such phase transfer catalysis processes as involving "simple experimental procedures, mild reaction conditions, inexpensive and environmentally benign reagents and solvents and the possibility of conducting large-scale preparations." Thus, asymmetric phase transfer catalysis remains an important area for organic chemistry research.
    [0002] The present invention is directed to novel bis-quarternary cinchona alkaloid salts and the use of bis-quarternary cinchona alkaloid salts in asymmetric phase transfer catalysis. On certain substrates and under specific reaction conditions, the inventors have discovered that the use of bis-quarternary cinchona alkaloid salts in asymmetric phase transfer catalysis surprisingly provides for a more active and efficient process as compared to mono-quarternary catalysts, providing high efficiency rates and asymmetric products in high enantiomeric excess. SUMMARY OF THE INVENTION
    [0003] The invention is directed to novel bis-quarternary cinchona alkaloid salts and the use of bis-quarternary cinchona alkaloid salts in asymmetric phase transfer catalysis. DETAILED DESCRIPTION OF THE INVENTION
    [0004] The invention encompasses bis-quarternary cinchona alkaloid salts having the chemical structure of Formula I:
    [0005] Unless depicted or specified otherwise, the cinchona alkaloid salts of Formula I encompass all stereoisomers, including cinchonine, cinchonidine, quinine, quinidine, dihydroquinidine, and dihydroquinine.
    [0006] In an embodiment, the invention encompasses the bis-quarternary cinchona alkaloid salts of Formula I for use as phase transfer catalysts in one of the following asymmetric reactions: (1) alkylation with an electrophilic alkylating agent, (2) Michael addition with an electron deficient olefin, (3) aldol reaction with an aldehyde, (4) Mannich reaction with a α-imino ester, (5) Darzens reaction with an aldehyde, (6) Neber rearrangement of an oxime into an α-aminoketone, (7) epoxidation of an electron deficient olefin, (8) aziridination of an electron deficient olefin, (9) dihydroxylation of an electron deficient olefins, (10) fluorination of a carbonyl substrate, and (11) sulfenylation of a β-keto sulfoxide. The aforementioned reactions are well know in the art and described by Maruoka.
    [0007] Another embodiment of the invention encompasses a process for stereoselectively producing a compound of Formula A
    [0008] Within this embodiment, the invention encompasses the aforementioned process wherein in Formula A each RA and each RB are independently selected from the group consisting of:(i) hydrogen, (ii) halogen, (iii) OR7, (iv) N(R7)2, (v) CN, (vi) C1-8alkyl or C2-8alkenyl, either of which optionally bears up to 3 substituents independently selected from halogen, OH, CN, CF3, OR7, SR8, SO2R8, SO2N(R7)2, COR7, CO2R7, CON(R7)2, N(R7)2, NR7COR8 and NR7SO2R8; and (vii) C3-10cycloalkyl, C3-10cycloalkylC1-4alkyl, Het, HetC1-4alkyl, ARY or ARY-C1-4alkyl, any of which optionally bears up to 3 substituents independently selected from halogen, OH, oxo, CN, CF3, R8, OR7, SR8, SO2R8, SO2N(R7)2, COR7, CO2R7, CON(R7)2, N(R7)2, NR7COR8 and NR7SO2R8; where "ARY" refers to phenyl or 5- or 6-membered heteroaryl, either of which phenyl or heteroaryl is optionally fused to a 5- or 6-membered carbocycle or heterocycle, and "Het" refers to a nonaromatic mono- or bicyclic heterocyclic system of up to 10 ring atoms; and one of RA and RB together may complete a mono- or bicyclic carbocyclic or heterocyclic system of up to 10 ring atoms which optionally bears up to 3 substituents independently selected from halogen, OH, oxo, CN, CF3, R8, OR7, SR8, SO2R8, SO2N(R7)2, COR7, CO2R7, CON(R7)2, N(R7)2, NR7COR8 and NR7SO2R8;R7 is H or C1-6alkyl which is optionally substituted with up to 3 halogen atoms or with OH, CN, CF3, C1-4alkoxy, amino, C1-4alkylamino or di(C1-4alkyl)amino, or R7 is phenyl, benzyl or 5- or 6-membered heteroaryl, any of which optionally bears up to 3 substituents independently selected from halogen, OH, CN, CF3, C1-4alkyl, C1-4alkoxy, amino, C1-4alkylamino and di(C1-4alkyl)amino;or two R7 groups attached to the same nitrogen atom may complete a heterocycle of up to 6 ring atoms which optionally bears up to 3 substituents independently selected from halogen, OH, oxo, CN, CF3, C1-4alkyl, C1-4alkoxy, amino, C1-4alkylamino and di(C1-4alkyl)amino; andR8 is C1-6alkyl which is optionally substituted with up to 3 halogen atoms or with OH, CN, CF3, C1-4alkoxy, amino, C1-4alkylamino or di(C1-4alkyl)amino, or R8 is phenyl, benzyl or 5- or 6-membered heteroaryl, any of which optionally bears up to 3 substituents independently selected from halogen, OH, CN, CF3, C1-4alkyl, C1-4alkoxy, amino, C1-4alkylamino and di(C1-4alkyl)amino;or two R8 groups attached to the same nitrogen atom may complete a heterocycle of up to 6 ring atoms which optionally bears up to 3 substituents independently selected from halogen, OH, oxo, CN, CF3, C1-4alkyl, C1-4alkoxy, amino, C1-4alkylamino and di(C1-4alkyl)amino.
    [0009] Also within this embodiment, the invention encompasses the aforementioned process wherein in Formula A RC is selected from the group consisting of: (i) hydrogen, (ii) halogen, (iii) OR7, (iv) N(R7)2, (v) CN, (vi) C1-8alkyl or C2-8alkenyl, either of which optionally bears up to 3 substituents independently selected from halogen, OH, CN, CF3, OR7, SR8, SO2R8, SO2N(R7)2, COR7, CO2R7, CON(R7)2, N(R7)2, NR7COR8 and NR7SO2R8; and (vii) C3-10cycloalkyl, C3-10cycloalkylC1-4alkyl, Het, HetC1-4alkyl, ARY or ARY-C1-4alkyl, any of which optionally bears up to 3 substituents independently selected from halogen, OH, oxo, CN, CF3, R8, OR7, SR8, SO2R8, SO2N(R7)2, COR7, CO2R7, CON(R7)2, N(R7)2, NR7COR8 and NR7SO2R8; where "ARY" refers to phenyl or 5- or 6-membered heteroaryl, either of which phenyl or heteroaryl is optionally fused to a 5- or 6-membered carbocycle or heterocycle, and "Het" refers to a nonaromatic mono- or bicyclic heterocyclic system of up to 10 ring atoms; R7 is H or C1-6alkyl which is optionally substituted with up to 3 halogen atoms or with OH, CN, CF3, C1-4alkoxy, amino, C1-4alkylamino or di(C1-4alkyl)amino, or R7 is phenyl, benzyl or 5- or 6-membered heteroaryl, any of which optionally bears up to 3 substituents independently selected from halogen, OH, CN, CF3, C1-4alkyl, C1-4alkoxy, amino, C1-4alkylamino and di(C1-4alkyl)amino;or two R7 groups attached to the same nitrogen atom may complete a heterocycle of up to 6 ring atoms which optionally bears up to 3 substituents independently selected from halogen, OH, oxo, CN, CF3, C1-4alkyl, C1-4alkoxy, amino, C1-4alkylamino and di(C1-4alkyl)amino; andR8 is C1-6alkyl which is optionally substituted with up to 3 halogen atoms or with OH, CN, CF3, C1-4alkoxy, amino, C1-4alkylamino or di(C1-4alkyl)amino, or R8 is phenyl, benzyl or 5- or 6-membered heteroaryl, any of which optionally bears up to 3 substituents independently selected from halogen, OH, CN, CF3, C1-4alkyl, C1-4alkoxy, amino, C1-4alkylamino and di(C1-4alkyl)amino;or two R8 groups attached to the same nitrogen atom may complete a heterocycle of up to 6 ring atoms which optionally bears up to 3 substituents independently selected from halogen, OH, oxo, CN, CF3, C1-4alkyl, C1-4alkoxy, amino, C1-4alkylamino and di(C1-4alkyl)amino.
    [0010] Also within this embodiment, the invention encompasses the aforementioned process wherein in Formula A PG is selected from the group consisting of: C1-6 alkyl, vinyl, C(O)-O-L, C(O)-L, aryl, hetroaryl, benzyl, benzhydryl, trityl and C1-6alkoxymethyl, wherein aryl, heteroaryl, benzyl, benzyhydryl and trityl optionally are substituted with 1 to 3 substituents independently selected from methoxy and nitro, C1-6alkoxymethyl is optionally substituted with trimethylsilyl and L is C1-6alkyl, aryl or benzyl.
    [0011] Also within this embodiment, the invention encompasses the aforementioned process wherein in Formula A W is selected from the group consisting of: halogen and sulfonate.
    [0012] Also within this embodiment, the invention encompasses the aforementioned process wherein the water-immiscible organic phase is selected from the group consisting of benzene, toluene, xylenes, chlorobenzene, ethyl ether, isopropyl ether, tetrahydrofuran, 2-methyl tetrahydrofuran, dioxane, methyl tert-butyl ether, cyclopentyl methyl ether, isopropyl acetate, ethyl acetate, hexanes, heptanes, cyclohexane, dichloromethane and dichloroethane.
    [0013] Also within this embodiment, the invention encompasses the aforementioned process the base is selected from the group consisting of: sodium hydroxide, lithium hydroxide, potassium hydroxide, sodium carbonate, lithium carbonate, potassium carbonate, cesium hydroxide, cesium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, lithium hydrogen carbonate, cesium hydrogen carbonate, lithium fluoride, sodium fluoride, potassium fluoride, cesium fluoride, lithium tert-butoxide, sodium tert-butoxide, potassium tert-butoxide, sodium phosphate, lithium phosphate and potassium phosphate.
    [0014] Also within this embodiment, the invention encompasses the aforementioned process wherein the water-immiscible organic phase is toluene and the base is sodium hydroxide.
    [0015] The invention also encompasses the bis-quarternary cinchona alkaloid salts of Formula I for use as a phase transfer catalyst in one of the following reactions: (1) the asymmetric formation of a carbon-carbon bond at position b of a substrate having the following formula
    [0016] The invention also encompasses bis-quarternary cinchona alkaloid salts having the chemical structure of Formula II:
    [0017] Unless depicted or specified otherwise, the cinchona alkaloid salts of Formula II encompass all stereoisomers, including cinchonine, cinchonidine, quinine, quinidine, dihydroquinidine, and dihydroquinine.
    [0018] An embodiment of the invention encompasses bis-quarternary cinchona alkaloid salts of Formula II wherein Ar1 is phenyl which is optionally substituted with one to five substituents independently selected from R3, and Ar2 is phenyl which is optionally substituted with one to five substituents independently selected from R3.
    [0019] An embodiment of the invention encompasses bis-quarternary cinchona alkaloid salts of Formula IIa
    [0020] An embodiment of the invention encompasses bis-quarternary cinchona alkaloid salts of Formula IIa wherein R1 is vinyl and R2 is methoxy.
    [0021] Another embodiment of the invention encompasses bis-quarternary cinchona alkaloid salts of Formula IIa wherein R3 is selected from halogen and methoxy.
    [0022] Another embodiment of the invention encompasses a bis-quarternary cinchona alkaloid salt selected from:
    [0023] As used herein, the term "alkyl" refers to a monovalent straight or branched chain, saturated aliphatic hydrocarbon radical having a number of carbon atoms in the specified range. Thus, for example, "C1-6 alkyl" (or "C1-C6 alkyl") refers to any of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and t-butyl, n- and iso- propyl, ethyl and methyl. As another example, "C1-4 alkyl" refers to n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl. As another example, "C1-3 alkyl" refers to n-propyl, isopropyl, ethyl and methyl.
    [0024] The term "haloalkyl" means an alkyl radical as defined above, unless otherwise specified, that is substituted with one to five, preferably one to three halogen. Representative examples include, but are not limited to trifluoromethyl, dichloroethyl, and the like.
    [0025] The term acyl, means -C(O)-alkyl where alkyl is as defined above.
    [0026] The term "alkoxy" means -O-alkyl where alkyl is as defined above.
    [0027] The term "alkenyl" refers to a monovalent straight or branched chain, saturated aliphatic hydrocarbon radical having a number of carbon atoms in the specified range and at least one carbon-carbon double bond, and otherwise carbon-carbon single bonds. Alkenyl includes for example ethenyl, 1-methylethynyl, 2-propenenyl, 2-butenyl, 1,4-pentadienyl and the like.
    [0028] The term "alkynyl" refers to a monovalent straight or branched chain, saturated aliphatic hydrocarbon radical having a number of carbon atoms in the specified range and at least one carbon-carbon triple bond, and otherwise carbon-carbon double or single bonds. Alkynyl includes for example 2-propynyl, 1-butynyl, 3-hexen-5-ynyl and the like.
    [0029] The term "cycloalkyl" refers to any monocyclic ring of an alkane having a number of carbon atoms in the specified range. Thus, for example, "C3-6 cycloalkyl" (or "C3-C6 cycloalkyl") refers to cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl, and "C3-5 cycloalkyl" refers to cyclopropyl, cyclobutyl, and cyclopentyl.
    [0030] The term "halogen" (or "halo") refers to fluorine, chlorine, bromine and iodine (alternatively referred to as fluoro, chloro, bromo, and iodo).
    [0031] The term "aryl" refers to phenyl, naphthyl, and anthranyl.
    [0032] The term "heteroaryl" refers to (i) a 5- or 6-membered heteroaromatic ring containing from 1 to 3 heteroatoms independently selected from N, O and S, or (ii) is a heterobicyclic ring selected from quinolinyl, isoquinolinyl, and quinoxalinyl. Suitable 5- and 6-membered heteroaromatic rings include, for example, pyridyl (also referred to as pyridinyl), pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thienyl, furanyl, imidazolyl, pyrazolyl, triazolyl, oxazolyl, isooxazolyl, oxadiazolyl, oxatriazolyl, thiazolyl, isothiazolyl, and thiadiazolyl. Heteroaryls of particular interest are pyrrolyl, imidazolyl, pyridyl, pyrazinyl, quinolinyl (or quinolyl), isoquinolinyl (or isoquinolyl), and quinoxalinyl.
    [0033] Examples of 4- to 7-membered, saturated heterocyclic rings within the scope of this invention include, for example, azetidinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, isoxazolidinyl, pyrrolidinyl, imidazolidinyl, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrazolidinyl, hexahydropyrimidinyl, thiazinanyl, thiazepanyl, azepanyl, diazepanyl, tetrahydropyranyl, tetrahydrothiopyranyl, and dioxanyl. Examples of 4- to 7-membered, unsaturated heterocyclic rings within the scope of this invention (see HetB) include mono-unsaturated heterocyclic rings corresponding to the saturated heterocyclic rings listed in the preceding sentence in which a single bond is replaced with a double bond (e.g., a carbon-carbon single bond is replaced with a carbon-carbon double bond).
    [0034] It is understood that the specific rings listed above are not a limitation on the rings which can be used in the present invention. These rings are merely representative.
    [0035] Unless expressly stated to the contrary in a particular context, any of the various cyclic rings and ring systems described herein may be attached to the rest of the compound at any ring atom (i.e., any carbon atom or any heteroatom) provided that a stable compound results.
    [0036] Unless expressly stated to the contrary, all ranges cited herein are inclusive. For example, a heteroaromatic ring described as containing from "1 to 4 heteroatoms" means the ring can contain 1, 2, 3 or 4 heteroatoms. It is also understood that any range cited herein includes within its scope all of the sub-ranges within that range. Thus, for example, a heterocyclic ring described as containing from "1 to 4 heteroatoms" is intended to include as aspects thereof, heterocyclic rings containing 2 to 4 heteroatoms, 3 or 4 heteroatoms, 1 to 3 heteroatoms, 2 or 3 heteroatoms, 1 or 2 heteroatoms, 1 heteroatom, 2 heteroatoms, 3 heteroatoms, and 4 heteroatoms. As another example, an aryl or heteroaryl described as optionally substituted with "from 1 to 4 substituents" is intended to include as aspects thereof, an aryl or heteroaryl substituted with 1 to 4 substituents, 2 to 4 substituents, 3 to 4 substituents, 4 substituents, 1 to 3 substituents, 2 to 3 substituents, 3 substituents, 1 to 2 substituents, 2 substituents, and 1 substituent.
    [0037] When any variable occurs more than one time in any constituent or in Formula I, II, IIa, A, B or C, or in any other formula depicting and describing compounds of the present invention, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
    [0038] Unless expressly stated to the contrary, substitution by a named substituent is permitted on any atom in a ring (e.g., cycloalkyl, aryl, or heteroaryl) provided such ring substitution is chemically allowed and results in a stable compound.
    [0039] The compounds of the invention contain chiral centers and, as a result of the selection of substituents and substituent patterns, can contain additional chiral centers, and thus can occur as mixtures of stereoisomers, or as individual diastereomers, or enantiomers. All isomeric forms of these compounds, whether individually or in mixtures, are within the scope of the present invention. Unless depicted or specified otherwise, the cinchona alkaloid salts of the invention encompass all stereoisomers, including cinchonine, cinchonidine, quinine, quinidine, dihydroquinidine, and dihydroquinine.
    [0040] To the extent substituents and substituent patterns provide for the existence of tautomers (e.g., keto-enol tautomers) in the compounds of the invention, all tautomeric forms of these compounds, whether present individually or in mixtures, are within the scope of the present invention. Compounds of the present invention having a hydroxy substituent on a carbon atom of a heteroaromatic ring are understood to include compounds in which only the hydroxy is present, compounds in which only the tautomeric keto form (i.e., an oxo substitutent) is present, and compounds in which the keto and enol forms are both present.
    [0041] The term "organic substituent group" means any substituent group containing a carbon atom, which may be optionally substituted. Organic substituent groups include, but are not limited to, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, aryl, heteroaryl, non- or partially aromatic heterocycles, C3-10cycloalkyl, C1-10alkoxy, C1-10alkylthio, and C1-10acyl, each optionally substituted with, for example, one or more of the following: halide, hydroxy, nitrogen containing substituents such as amino, sulfur containing substituent such as sulfates, C1-4alkoxy and C1-4alkylthio.
    [0042] The term "nitrogen protecting group" means a substituent that protects a nitrogen atom in a reaction from a reagent or chemical environment. Nitrogen protecting groups are well known in the art and include for example, t-butyl, vinyl, phenyl, benzyl, p-methoxybenzyl, 3,4-dimethoxy benzyl, p-nitrobenzyl, benzhydryl, trityl, trialkylsilyl, methoxymethyl ether, (2,2,2-trichloroethoxy)methyl and 2-(trimethylsilyl)ethoxy)methyl, Boc, Cbz.
    [0043] The term "functional group that has leaving ability" means an atom or atom group that leaves from a substrate in a substitution or elimination reaction, that is a leaving group, and includes for example halogen and sulfonate.
    [0044] The term electrophilic alkylating agent" means an agent that delivers the equivalent of an alkyl cation, such as for example an alkyl halide.
    [0045] The term "electon deficient olefin" means an electrophilic alkene substituted with for example, a ketone, such as an α, β-unsaturated carbonyl, a nitrile or a nitro group.
    [0046] The term "sulfonate" means an anion or leaving group having the formula R#-SO3- which is the conjugate base of sulfonic acid. R# includes for example C1-4alkyl optionally substituted with 1 to 3 halogen, and aryl optionally substituted with 1 to 3 halogen or methyl or nitro. Examples include mesylate, triflate, tosylate and besylate.
    [0047] The term "electron withdrawing group" is well known in the art are includes for example, cyano, nitro, -C(O)ORxvii,-C(O)SRxviii and -C(O)NRxvixRxx, wherein Rxvii and Rxviii are independently H or an organic substituent group and Rxvix and Rxx are independently H or an organic substituent group or Rxvix and Rxx may be joined together with the nitrogen to which they are attached to form a 5- or 6-membered heterocyclic ring; ABBREVIATIONS
    [0048] The following abbreviations are used throughout the specification. DCM = dichloromethane DCPP = 1,3-bis(dicyclohexylphosphino)propane DHP = 3,4-dihydro-2H-pyran DMF = dimethylformamide DMSO = dimethyl sulfoxide HCl = hydrochloric acid IPA = isopropyl alcohol LCAP = liquid chromatography area percent MTBE = methyl tert-butyl ether NMP = N-methyl-2-pyrrolidone PTC = phase transfer catalyst RT = room temperature SFC = supercritical fluid chromatography THF = tetrahydrofuran EXAMPLE 1
    [0049]
    [0050]
    [0051] To a solution of 2,3-dibromo-5-chloropyridine (60 g, 221 mmol) in THF (500 mL) was added a solution of isopropylmagnesium chloride lithium chloride solution in THF (1.3M, 185 mL) at -40 °C over about 30 min. The solution was stirred for 30 min at -40 °C and DMF (50 mL) was added. The resulting solution was warmed up to room temperature and stirred for 30 min. The reaction was quenched with 1 N HCl (400 mL) and MTBE (200 mL) was added. Organic layer was separated and washed twice with 5% aqueous NaHCO3 (200 mL). The solvent was removed under vacuum at 50 °C. The resulting solids (aldehyde intermediate) were dissolved in methanol (400 mL). The solution was cooled to 5 °C under an ice bath. NaBH4 (3.6 g) was added slowly over 30 min while maintaining the reaction temperature below room temperature. The reaction mixture was stirred for another 30 min followed by addition of water (125 mL). The resulting mixture was concentrated under vacuum to approximately 150 ml. Solids precipitated during the concentration. The suspension was stirred vigorously at room temperature for 1 h and solids were collected by filtration. The wet cake was dried in a vacuum oven over night at 60 °C to give 1 (45.6 g, 93%) as a solid. 1H NMR (CDCl3, 400 MHz): δ 8.26 (d, J = 2.5 Hz, 1H), 7.88 (d, J =2.5 Hz, 1H), 4.73 (d, J = 5.8 Hz, 2H), 2.33 (t, J = 11.4 Hz, 1H); 13C NMR (CDCl3, 100 MHz): δ 147.12, 138.48, 138.39, 136.14, 132.06, 62.76. 5-Chloro-3-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)picolinaldehyde (2)
    [0052]
    [0053] To a solution of 1 (5.0 g, 22.5 mmol) in 2-MeTHF (15 mL) was added 3,4-dihydro-2H-pyran (2.7 mL, 29.6 mmol) and concentrated sulfuric acid (125 mg) at room temperature. The solution was stirred for 10 min and was then cooled to - 3 °C. Isopropylmagnesium chloride lithium chloride solution (1.3 M, 30 ml, 39 mmol) was slowly added at -3 to 3 °C. The resulting solution was stirred at -3 °C for 3 h until a HPLC showed the conversion was greater than 97%. DMF (5 ml) was added over 15 min below 5 °C. The resulting solution was stirred for another 1 h at this temperature. The reaction mixture was quenched by addition of MTBE (50 mL), 15% aqueous citric acid (25 mL) and water (15 mL). The organic layer was separated and washed with 5% aqueous NaCl (50 mL) twice. The organic solution was concentrated under vacuum at 50 °C to give 2 as an oil (6.2 g, 68 wt%, 16.6 mmol, 74% yield). The crude product was used directly for the next step without further purification. The pure sample was isolated by flash chromatography on silica gel with 5% ethyl acetate in hexane as eluants. 1H NMR (CDCl3, 400 MHz): δ 10.13 (s, 1H), 8.65 (s, 1H), 8.20 (s, 1H), 5.25 (d, J = 16.6 Hz, 1H), 5.01 (d, J = 16.6 Hz, 1H), 4.80 (m, 1H), 3.88 (m, 1H), 3.58 (m, 1H), 1.7 (m, 6H); 13C NMR (CDCl3, 100 MHz): δ 194.20, 147.06, 146.32, 138.98, 136.41, 134.87, 99.04, 64.42, 62.72, 30.53, 25.30, 19.66. (E)-1-(tert-Butyl)-3-((5-chloro-3-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)pyridin-2-yl)methylene)-1H-pyrrolo[2,3-b]pyridin-2(3H)-one (4)
    [0054]
    [0055] To a solution of crude 2 (6.2 g, 68 wt%, 16.6 mmol) and 3 (3.46 g, 18.3 mmol) in isopropanol (40 mL) was added DBU (0.12 g, 0.83 mmol) at - 2 °C. After stirring at -2 °C for 2 h, the solution was warmed up to 10 °C and stirred at this temperature for 3 h. The yellow solids precipitated from the solution. The suspension was stirred over night while the batch was allowed to warm up to room temperature slowly. The suspension was finally warm up to 50 °C and stirred for 4 h at this temperature. After cooling to 30 °C, water (35 ml) was added dropwise over 30 min from an additional funnel. The suspension was cooled to room temperature and filtered. The cake was washed with a mixture of isopropanol (3 mL) and water (3 mL). The precipitates were collected and dried in a vacuum oven over night at 50 °C to give 4 (6.2 g, 87%) as a solid. 1H NMR (CDCl3, 400 MHz): δ 8.72 (dd, J = 7.5, 1.8 Hz), 8.66 (d, J = 2.4 Hz, 1H), 8.18 (dd, J =5.1, 1.8 Hz, 1H), 7.94 (d, J = 2.4Hz, 1H), 7.78 (s, 1H, 1H), 6.89 (dd, J = 7.5, 5.1 Hz, 1H), 4.99 (d, J = 13.8 Hz, 1H), 4.80 (m, 1H), 4.70 (d, J = 13.8 Hz, 1H), 3.90 (m, 1H), 3.60 (m, 1H), 1.83 (s, 9H), 2.0-1.5 (m, 6H). The conformation of the double bond as trans isomer was confirmed by NOE experiment. 13C NMR (CDCl3, 100 MHz): δ 168.75, 159.64, 148.99, 147.85, 146.65, 137.01, 135.29, 133.56, 132.41, 129.50, 129.37, 117.27, 116.32, 98.77 64.80, 62.49, 58.62, 30.39, 29.01, 25.26, 19.34. 1-(tert-Butyl)-3-((5-chloro-3-(hydroxymethyl)pyridin-2-yl)methyl)-1H-pyrrolo[2,3-b]pyridin-2(3H)-one (5)
    [0056]
    [0057] To a suspension of 4 (3.0 g, 7.0 mmol) in ethanol (25 mL) was added NaBH4 (0.37 g) in one portion. The resulting suspension was stirred at room temperature for 1 h. The reaction was quenched by adding water (10 mL) followed by 6 N HCl solution in isopropanol (5 mL) slowly. The solution was warmed up to 40 °C and stirred for 3 h. The reaction mixture was mixed with MTBE (50 mL) and saturated aqueous NaCl (50 mL). The organic was separated and washed with water (50 mL). The solution was concentrated under vacuum at 50 °C and residue was triturated with hexane (30 mL). The resulting suspension was stirred at room temperature for 30 min. The precipitates were collected by filtration to give 5 (2.2 g, 86 %) as a solid. 1H NMR (CDCl3, 400 MHz): δ 8.34 (s, 1H), 8.15 (d, J = 4.9 Hz, 1H), 7.74 (s, 1H), 7.30 (d, J = 7.1 Hz, 1H), 6.83 (t, J = 5.7 Hz, 1H), 4.73 (dd, J = 13.4, 4.9 Hz, 1H), 4.63 (dd, J = 13.4, 5.7 Hz, 1H), 4.01 (t, J = 6.1 Hz, 1H), 3.44 (dd, J = 15.4, 5.2 Hz, 1H), 3.17 (dd, J = 15.4, 7.2 Hz, 1H), 2.94 (t, J = 5.5 Hz, 1H), 1.79 (s, 9H); 13C NMR (CDCl3, 100 MHz): δ 178.72, 159.12, 153.82, 146.45, 145.83 135.72, 135.32, 130.63, 130.27, 124.04, 117.33, 61.40, 58.70, 44.12, 34.01, 28.81. 1-(tert-Butyl)-3-((5-chloro-3-(chloromethyl)pyridin-2-yl)methyl)-1H-pyrrolo[2,3-b]pyridin-2(3H)-one (6)
    [0058]
    [0059] To a solution of 5 (5.8 g, 16.8 mmol) in dichloromethane (30 mL) was added DMF (60 µL) and thionyl chloride (2.2 g) at 5 °C. The mixture was stirred for 30 min at this temperature followed by addition of 5% aqueous NaCl (30 mL). The organic layer was separated and washed with 5% aqueous NaCl (30 mL). The solvent was removed and the residue was dissolved in heptane (20 mL). The solution was stirred for 30 min and the product was precipitated. The suspension was cooled to 0 °C and filtered to give 6 (5.8 g, 93%) as a solid: 1H NMR (CDCl3, 400 MHz): δ 8.36 (d, J = 2.3 Hz, 1H), 8.13 (dd, J = 5.1, 1.4 Hz, 1H), 7.65 (d, J = 2.3 Hz, 1H), 7.19 (om, 1H), 6.78 (dd, J = 7.3, 5.2 Hz, 1H), 4.58 (m, 2H), 4.06 (m, 1H), 3.66 (dd, J = 16.3, 4.6 Hz, 1H), 3.32 (dd, J = 16.3, 7.5 Hz, 1H), 1.75 (s, 9H); 13C NMR (CDCl3, 100 MHz): δ 178.06, 159.45, 154.58, 147.39, 145.73, 136.87, 132.47, 130.42, 130.11, 123.77, 117.03, 58.51, 43.37, 42.25, 33.69, 28.82. (S)-1'-(tert-Butyl)-3-chloro-5,7-dihydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one (7)
    [0060]
    [0061] A solution of 6 (2.39 g, 6.56 mmol) in toluene (50 mL) was cooled to -2.5 °C under nitrogen atmosphere. Compound 10 (17 mg, 0.020 mmol) was charged, and the resulting solution was aged for about 15 min while cooled to -3.3 °C. A pre-cooled (-1 °C) aqueous NaOH (26.2 mL, 0.3 N) was charged in over 4 min below -0.6 °C. The reaction was aged at -1.3 °C for 3 h. The reaction was quenched with water (10 ml). The organic layer was washed with water (10 mL), concentrated, flushed with IPA to give crude product 7 (2.59 g, 94.4%ee, 83% wt by NMR against 1,3,5-trimethoxybenzene as an internal standard).
    [0062] The crude product was recrystallized from IPA and water, filtered and dried in an oven at 50 °C to give 58 (1.95 g, 95.7%wt, 99%ee, 87% yield) as a solid. 1H NMR (CDCl3, 400 MHz): δ 8.42 (s, 1H), 8.19 (d, J = 5.2 Hz, 1H), 7.56 (s, 1H), 7.10 (d, J = 7.3 Hz, 1H), 6.83 (dd, J = 7.3, 5.2 Hz, 1H), 3.60 (dd, J = 24.9, 16.8 Hz, 2 H), 3.09 (dd, J = 28.6, 16.8 Hz, 2H); 13C NMR (CDCl3, 100 Hz): δ 179.43, 160.54, 157.82, 147.44, 146.54, 135.80, 132.17, 130.62, 129.33, 128.36, 117.69, 58.83, 51.94, 44.35, 41.57, 28.83. (1S,2R,4S,5R)-1-(2-Bromo-5-methoxybenzyl)-2-((S)-(1-(2-bromo-5-methoxybenzyl)-6-methoxyquinolin-1-ium-4-yl)(hydroxy)methyl)-5-vinylquinuclidin-1-ium bromide (10)
    [0063]
    [0064] A slurry of quinidine (11, 8.1 g, 23.7 mmol, containing ∼14% dihydroquinidine) and 2-bromo-5-methoxybenzylbromide (12, 16.59 g, 59.3 mmol) in IPA (4.0 ml) and DMF (28.4 mL) was degassed by vacuum and flushed with N2, then heated to 70 °C for 7 h. The reaction mixture was cooled to 22 °C, this reaction solution was charged to AcOEt (320 ml) at 22 °C over 10 min while stirring. The resulting slurry was aged at 22 °C for 1 to 2 h, filtered, rinsed with AcOEt (2 x 24 ml), then hexane (2 x 24 ml). The solid was dried under vacuum to give powder as a mixture of bis-salts (bis-quinidine salt 10 and bis-dihydroquinidine salt). (Total 19.7 g, 94% yield). The authentic sample of 10 was purified by SFC (IC column, 20 x 250 mm, 60% MeOH/CO2, 50 mL/min, 100 bar, 35°C, 220 nm, sample concentration: 133 mg/mL in MeOH; desired peak: 3 to 4.5 min). 1H NMR (CDCl3, 500 MHz): δ 9.34 (d, J = 6.1 Hz, 1H), 8.46 (d, J = 6.1 Hz, 1H), 8.38 (d, J = 9.7 Hz, 1H), 8.0 (dd, J = 9.7, 2.1 Hz, 1H), 7.86 (s, 1H), 7.79 (d, J = 8.9 Hz, 1H), 7.74 (d, J = 8.9 Hz, 1H), 7.60 (d, J = 2.5 Hz, 1H), 7.42 (d, J = 2.3 Hz, 1H), 7.17 (dd, J = 8.8, 2.8 Hz, 1H), 7.03 (dd, J = 8.8, 2.7 Hz, 1H), 6.93 (s, 1H), 6.50 (d, J = 2.4 Hz, 1 H), 6.06 (m, 1H), 5.24 (m, 3H), 4.95 (d, J = 12.9 Hz, 1H), 4.37 (m, 1H), 4.23 (m, 4H),4.12 (m, 1H), 3.88 (s, 3H), 3.69 (s, 3H), 3.54 (m, 1H), 3.32 (s, 2H), 3.23 (m, 1H), 2.71 (m, 1H), 2.51 (s, 2H), 2.33 (m, 1H), 1.94 (br, 1H), 1.83 (br, 2H), 1.17 (br, 1H); 13C NMR (DMSO-d6, 100 Hz): δ 159.45, 159.07, 158.67, 156.12, 146.01, 137.08, 134.68, 134.30, 133.21, 132.98, 128.18, 128.03, 127.45, 122.13, 121.89, 121.22, 118.08, 117.5, 117.07, 116.73, 116.20, 115.81, 112.67, 105.09, 66.81, 65.51, 62.43, 56.75, 56.06, 55.91, 55.52, 54.80, 36.84, 25.91, 23.10, 20.75. (S)-1'-(tert-Butyl)-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxylic acid (8)
    [0065]
    [0066] A mixture of 7 (5.0 g, 14.5 mmol), K2CO3 (5.01 g, 36.2 mmol), Pd(OAc)2 (33 mg, 0.145 mmol), 1,3-bis(dicyclohexylphosphino)propane (DCPP, 127 mg, 0.290 mmol) and water (0.522 mL, 29.0 mmol) in NMP (32 mL) was heated at 120 °C under 30 psi of CO for 24 h. After cooling to room temperature, the resulted slurry was diluted with water (100 mL). The pH was slowly adjusted to 3∼4 with 2 N HCl. The slurry was aged at room temperature for 1 h, filtered, rinsed with water (40 to 50 mL), dried under oven at 60 °C to give 8 (4.64 g, 95%) as a solid. 1H NMR (DMSO-d6, 500 MHz): δ 8.90 (s, 1H), 8.19 (d, J = 5.2 Hz, 1H), 7.54 (d, J = 7.3 Hz, 1H,), 6.99 (dd, J = 7.3, 5.2 Hz, 1H), 3.33 (m, 4H), 1.72 (s, 9H); 13C NMR (DMSO-d6, 125 MHz): δ 180.16, 167.44, 166.97, 158.07, 149.76, 146.61, 135.39, 133.09, 130.36, 128.81, 125.48, 118.44, 58.19, 51.12, 44.56, 41.24, 28.91. (S)-2'-Oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxylic acid (9)
    [0067]
    [0068] To 8 (4 g, 97%wt) was charged 37% HCl (40 to 44 mL). The slurry was heated at 94 °C for up to 48 h, cooled down to room temperature. The solvent was partially removed by reducing pressure to about total 2 vol (∼ 4 mL water remained). The residue was diluted with water (20 mL) followed by adjusting pH to 2.6 with NaOH (3.5 N, 4.5 mL). The thick slurry was aged for 1 to 2 h, filtered, rinsed with water (2 x 8 mL), followed by water/acetone (1:1, 8 mL). The wet cake was dried to give compound 9 (3.1 g, 98%wt, 94%) as crystals. 1H NMR (DMSO-d6, 500 MHz): δ 13.31(br, 1H), 11.14 (s, 1H), 8.91 (s, 1H), 8.11 (m, 2H), 7.49 (dd, J = 7.3, 1.3 Hz, 1H), 6.93 (dd, J = 7.3, 5,3 Hz, 1H), 3.36 (m, 4H); 13C NMR (DMSO-d6, 125 MHz): δ 181.06, 167.36, 166.95, 156.80, 149.79, 147.32, 135.37, 133.19, 130.73, 128.88, 125.50, 118.46, 51.78, 44.12, 40.70. 1-(tert-Butyl)-1H-pyrrolo[2,3-b]pyridin-2(3H)-one (3)
    [0069]
    [0070] A mixture of compound 3a (10.0 g, 40.3 mmol), NaCl (2.9g, 1.25 eq.) and water (2 mL) in DMSO (50 mL) was heated at 120 °C for 30 min. The mixture was cooled to 30 °C followed by addition of MTBE (200 mL) and water (50 mL). The organic layer was separated and the aqueous layer extracted with another MTBE (50 mL). Combined organic layer was washed three times with water (50 mL). Solvent removed under vacuum and the resulting solid was dried in a vacuum oven at 30 °C to give 3 (7.0 g, 92%) as solid. 1H NMR (CDCl3, 400 MHz): δ 8.15 (dd, J = 5.2, 1.4 Hz, 1H), 7.40 (dd, J = 7.2, 1.4 Hz, 1H), 6.88 (dd, J = 7.2, 5.2 Hz, 1H), 3.45 (s, 2H), 1.78 (s, 9H). 13C NMR (CDCl3, 100 MHz): δ 174.99, 160.06, 145.82, 130.80, 119.51, 117.15, 58.53, 35.98, 28.80; EXAMPLE 2
    [0071]
    [0072]
    [0073] To a solution of compound 13 (5.0 g, 15.7 mmol) in 2-MeTHF (12 mL) was added 3,4-dihydro-2H-pyran (2 mL, 20.4 mmol) and concentrated sulfuric acid (0.06 mL) at room temperature. The solution was stirred for 10 min and was then cooled to - 3 °C. Isopropylmagnesium chloride lithium chloride solution (21 mL, 1.3 M, 26.7 mmol) was slowly added at -3 to 3 °C. The resulting solution was stirred at -3 °C for 3 h until a HPLC showed the conversion was greater than 97%. DMF (4 ml) was added over 15 min below 5 °C. The resulting solution was stirred for another one hour at this temperature. The reaction mixture was quenched by addition of MTBE (40 mL), 15% aqueous citric acid (20 mL) and water (12 mL). The organic layer was separated and washed twice with 5% aqueous NaCl (40 mL). The solution was concentrated under vacuum at 50 °C to give 4.65 g of 14 as oil (97 %wt, 98% yield). The crude product was used directly for the next step without further purification. 1-(tert-Butyl)-3-(2-(hydroxymethyl)-5-(trifluoromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-2(3H)-one (15)
    [0074]
    [0075] To a round bottom flask was charged 14 (4.50 g , 15.6 mmol), 3 (2.50 g. 17.2 mmol, 1.1 eq.) and IPA (25 ml). This slurry was aged until dissolved. It was cooled under an ice bath followed by charging DBU (0.12 mL, 0.8 mmol) then was aged for half hour below 5 °C and 2 h at room temperature. The reaction mixture was degassed by vacuum and flushed with N2 followed by charge NaBH4 (0.80g, 21.8 mmol). The reaction was aged for 2 h. After completion of the reduction, 6 N HCl (10 mL) and water (16 mL) was added in and the mixture was heated to 70 °C for 1 to 2 h until the deprotection of THP was complete. The resulting reaction mixture was concentrated followed by charge dichloromethane (60 mL) and water (27 mL). The pH of the reaction mixture was adjusted to ∼10 with aqueous NaOH, and the organic layer was separated. The aqueous layer was then extracted with dichloromethane (50 mL) twice. The combined organic layer was concentrated under vacuum, and purified with silica gel column (0 to 30% of AcOEt/hexane) to give the desired product 15 as a solid (4.07 g, 78%).1H NMR (CDCl3, 500 MHz): δ 8.21 (dd, J =5.2, 0.8 Hz, 1H), 7.59 (d, J = 8.1 Hz, 1H), 7.52 (dd, J = 8.0, 1.1 Hz, 1H), 7.19 (om, 2H), 6.90 (dd, J = 7.3, 5.3 Hz, 1H), 4.78 (ABq, J = 12.9 Hz, 2H), 3.71 (m, 1H), 3.45 (dd, J = 14.2, 4.4Hz, 1H), 3.22 (dd, J = 14.2, 4.4 Hz, 1H), 2.77 (br, 1H), 1.67 (s, 9H); 13C NMR (CDCl3, 125 MHz): δ 176.6, 159.1, 146.3, 140.1, 137.4, 131.13, 131.10, 130.7 (q, J = 33.8 Hz), 127.3, 124.3, 123.5 (q, J = 272 Hz), 122.5, 117.1, 58.7, 45.7, 43.0, 33.0, 28.7. 1-(tert-Butyl)-3-(2-(chloromethyl)-5-(trifluoromethyl)benzyl)-1H-pyrrolo[2,3-b]pyridin-2(3H)-one (16)
    [0076]
    [0077] To a solution of 15 (3.5g, 10.4 mmol) in dichloromethane (20 mL) was charged DMF (0.04 mL, 0.5 mmol). This solution was cooled under an ice bath. Thionyl chloride (0.85 mL, 11.5 mmol) was then added under 5 °C, and the resulting reaction was aged for 3 h at this temperature. Once the reaction was complete, 5% aqueous NaCl (16.5 mL) was added. The organic layer was separated and washed with 5% aqueous NaCl (16.5 mL). The solvent was removed via rotovap, and the crude was purified by silica gel column chromatography (0 to 10% AcOEt/hexane) to give the desired compound 16 as an oil (3.05 g, 74%). 1H NMR (CDCl3, 500 MHz): δ 8.20 (dd, J = 5.1, 1.7 Hz, 1H), 7.58 (d, J = 8.1 Hz, 1H), 7.51 (dd, J = 8.1, 1.1 Hz, 1H), 7.18 (s, 1H), 7.12 (dd, J = 6.3, 2.7 Hz, 1H), 6.88 (dd, J = 7.3, 5.1 Hz, 1H), 4.77 (ABq, J = 12.9 Hz, 2H), 3,72 (m, 1H), 3.46 (dd, J = 14.2, 4.4, 1H), 3.18 (dd, J = 14.2, 8.7 Hz, 1H), 1.67 (s, 9H); 13C NMR (CDCl3, 125 MHz): δ 177.6, 159.1, 146.5, 143.3, 136.6, 131.0, 129.7 (m, 2C), 124.0, 123.0, 123.9 (q, J = 271 Hz), 117.4, 126.6, 62.4, 58.8, 46.1, 32.9, 28.6. 1'-(tert-Butyl)-5-(trifluoromethyl)-1,3-dihydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one (17)
    [0078]
    [0079] A solution of 16 (50 mg, 0.126 mmol) in toluene (2 ml) was cooled to -1 °C, degassed with vacuum and flushed N2. To this solution was charged a precooled (-2 to 0 °C) aqueous NaOH (IN, 1 mL) followed by charged a catalyst 18. The resulted reaction was aged at - 1 to 1 °C for several hours until complete conversion. The organic layer was purified with silica gel column chromatography (0 to 10% AcOEt/hexane) to give the desired compound 17 as oil (42 mg, 92%IY, 85%ee, R or S undetermined).1H NMR (CDCl3, 400 MHz): δ 8.17 (dd, J = 5.2, 1.8 Hz, 1H), 7.52 (m, 2 H), 7.37 (d, J = 8.2 Hz, 1H), 7.02 (dd, J = 7.3, 1.8 Hz, 1H), 6.80 (dd, J = 7.3, 5.2 Hz, 1H), 3.64 (d, J = 15.9 Hz, 2H), 3.09 (d, J = 16.1 Hz, 2H), 1.83 (s, 9H); 13C NMR (CDCl3, 125 MHz): δ 179.6, 157.6, 146.3, 145.3, 141.9, 129.8, 129.6 (q, J = 32 Hz), 127.6, 124.8, 124.5 (q, J = 271 Hz), 121.4, 117.6, 58.7, 53.8, 43.8, 43.7, 28.9. (1S,2S,4S,5R)-1-(2-Cyanobenzyl)-2-((R)-hydroxy(quinolin-4-yl)methyl)-5-vinylquinuclidin-1-ium bromide (19) and (1S,2S,4S,5R)-1-(2-cyanobenzyl)-2-((R)-hydroxy(1-(4-(trifluoromethyl)benzyl)quinolin-1-ium-4-yl)methyl)-5-vinylquinuclidin-1-ium bromide (18)
    [0080]
    [0081] A slurry cinchonidine (5.0 g, 16.98 mmol) and 2-cyano-benzyl bromide (4.0 g, 20.38 mmol) in 50 ml of IPA was degassed by vacuum and flushed with N2, then it was heated to 67 °C until completely conversion (4 to 5 h). It was cooled down and ∼40 mL of solvent was removed by reducing pressure. This concentrated solution was added into AcOEt (160 ml) over 5 to 10 min while stirring. The resulting slurry was aged for 1 to 2 h at 22 °C, filtered, rinsed with IPA/hexane (1:1; 50 ml) and dried under vacuum to give 19 as a solid (7.43 g, 89% IY).1H NMR(DMSO-d6, 500 MHz): δ 9.00 (d, J = 4.5 Hz, 1H), 8.39 (d, J = 8.4 Hz, 1H), 8.17 (d, J = 7.6 Hz, 1H), 8.12 (d, J = 7.6 Hz, 2H), 7.97 (t, J = 7.8 Hz, 1H), 7.85 (m, 3H), 7.76 (t, J = 8.2 Hz, 1H), 6.87 (d, J = 30 Hz, 1H), 6.58 (s, 1H), 5.72 (m, 1H), 5.33 (q, J = 13.1 Hz, 2H), 5.21 (d, J = 17.3 Hz, 1H), 4.96 (d, J = 10.6 Hz, 1H), 4.47 (br, 1H), 4.07 (t, J = 9.8 Hz, 1H), 3.94 (dt, J = 12.0, 3.6 Hz, 1H), 3.44 (t, J = 12.0 Hz, 1H), 3.30 (dt, J = 11.5, 4.1 Hz, 1H), 2.68 (br, 1H), 2.13 (m, 2H), 2.02 (s, 1H), 1.81 (m, 1H), 1.22 (m, 1H); 13C NMR(DMSO-d6, 125 MHz): δ 150.1, 147.6, 145.0, 138.0, 135.7, 134.3, 133.6, 131.1, 130.8, 129.8, 129.4, 127.1, 124.2, 123.6, 120.0, 117.8, 116.4, 115.7, 67.7, 64.7, 60.4, 59.3, 51.2, 37.0, 25.5, 24.3, 21.1. Preparation of 18
    [0082] A slurry of 19 (0.15 g, 0.306 mmol) and 2-nitrobenzyl bromide (0.104 g, 0.61 mmol) in IPA (0.075 mL) and DMF (0.53 mL) was degassed by vacuum and flushed with N2, then it was heated to 70 °C until completely conversion (4 to 5 h). It was cooled down and was added into AcOEt (6 ml) over 5 to 10 min. The resulting slurry was aged for 1 to 2 h at 22 °C, filtered, rinsed AcOEt (2 x 5 ml) and dried under vacuum to give 18 as a solid (0.19 g, 94%IY).1H NMR(DMSO-d6, 500 MHz): δ 9.82 (d, J = 6.3 Hz, 1H), 8.81 (d, J = 8.5 Hz, 1H), 8.55 (m, 1H), 8.30 (t, J = 7.4 Hz, 1H), 8.13 (m, 3H), 8.0 (t, J = 7.4 Hz, 1H), 7.82 (m, 3H), 7.63 (d, J = 8.1 Hz, 2H), 7.45 (d, J = 3.5 Hz, 1H), 6.86 (s, 1H), 6.50 (m, 2H), 6.5 (m, 2H), 5.70 (m, 1H), 5.33 (s, 2H), 5.21 (d, J = 17.4 Hz, 1H), 4.99 (d, J = 10.5 Hz, 1H), 4.49 (m, 1H), 4.15 (m, 1H) 3.90 (m, 1H), 3.53 (m, 1H), 3.38 (m, 1H), 2.70 (br, 1H), 2.10 (m, 3H), 1.88 (m, 1H), 1.48 (m, 1H); 13C NMR(DMSO-d6, 125 MHz): δ 158.4, 149.8, 138.3, 138.0, 137.2, 135.8, 135.6, 134.3, 133.7, 131.2, 130.6, 130.5, 129.2 (q, J = 32.0 Hz), 128.3 (2C), 126.7, 126.2, 125.99, 125.96, 123.9 (q, J = 272.5 Hz), 122.8,121.6, 119.8, 117.8, 116.7, 115.7, 67.3, 65.4, 60.4, 59.7, 59.4, 51.3,37.0, 30.9, 25.5, 24.9, 22.0. RESULTS
    [0083] As shown in Table 1, the bis-quaternary catalyst is much more active and efficient as compared to the mono-quaternary catalyst for the spirocyclization reaction shown. For this experiment, the bis-catalysts contained ∼12 to 15% of the double saturated compounds hydroquinidine or hydrocinchonine. Table 1
    [0084] Tables 2 and 3 show a SAR study of bis-quaternary PTC catalysts for spirocyclization. Both bis-quaternary quinidine and cinchonine catalysts are very efficient (Entries 2 to 5). The Bis-Quinidine catalyst is relatively better than bis-cinchonine catalyst (Entry 2 and 3). 2-Bromo-5-Methoxy-benzyl group is the optimized group for this reaction. Table 2
    [0085] Table 4 shows a study of different functional groups. Table 4
    [0086] Table 5 shows a study of different ring systems; Doubly quaternized PTC is a more active catalyst than mono quaternized PTC. Table 5
    PTC 19: 3%ee Absolute configulation (R or S) has not been determined. PTC 18: 85%ee
    权利要求:
    Claims (8)
    [0001] A process for stereoselectively producing a compound of Formula A
    [0002] The process according to Claim 1 wherein each RA and each RB are independently selected from the group consisting of:
    (i) hydrogen,
    (ii) halogen,
    (iii) OR7,
    (iv) N(R7)2,
    (v) CN,
    (vi) C1-8alkyl or C2-8alkenyl, either of which optionally bears up to 3 substituents independently selected from halogen, OH, CN, CF3, OR7, SR8, SO2R8, SO2N(R7)2, COR7, CO2R7, CON(R7)2, N(R7)2, NR7COR8 and NR7SO2R8; and
    (vii) C3-10cycloalkyl, C3-10cycloalkylC1-4alkyl, Het, HetC1-4alkyl, ARY or ARY-C1-4alkyl, any of which optionally bears up to 3 substituents independently selected from halogen, OH, oxo, CN, CF3, R8, OR7, SR8, SO2R8, SO2N(R7)2, COR7, CO2R7, CON(R7)2, N(R7)2, NR7COR8 and NR7SO2R8; where "ARY" refers to phenyl or 5- or 6-membered heteroaryl, either of which phenyl or heteroaryl is optionally fused to a 5- or 6-membered carbocycle or heterocycle, and "Het" refers to a nonaromatic mono- or bicyclic heterocyclic system of up to 10 ring atoms;and one of RA and RB together may complete a mono- or bicyclic carbocyclic or heterocyclic system of up to 10 ring atoms which optionally bears up to 3 substituents independently selected from halogen, OH, oxo, CN, CF3, R8, OR7, SR8, SO2R8, SO2N(R7)2, COR7, CO2R7, CON(R7)2, N(R7)2, NR7COR8 and NR7SO2R8;R7 is H or C1-6alkyl which is optionally substituted with up to 3 halogen atoms or with OH, CN, CF3, C1-4alkoxy, amino, C1-4alkylamino or di(C1-4alkyl)amino, or R7 is phenyl, benzyl or 5- or 6-membered heteroaryl, any of which optionally bears up to 3 substituents independently selected from halogen, OH, CN, CF3, C1-4alkyl, C1-4alkoxy, amino, C1-4alkylamino and di(C1-4alkyl)amino;or two R7 groups attached to the same nitrogen atom may complete a heterocycle of up to 6 ring atoms which optionally bears up to 3 substituents independently selected from halogen, OH, oxo, CN, CF3, C1-4alkyl, C1-4alkoxy, amino, C1-4alkylamino and di(C1-4alkyl)amino; andR8 is C1-6alkyl which is optionally substituted with up to 3 halogen atoms or with OH, CN, CF3, C1-4alkoxy, amino, C1-4alkylamino or di(C1-4alkyl)amino, or R8 is phenyl, benzyl or 5- or 6-membered heteroaryl, any of which optionally bears up to 3 substituents independently selected from halogen, OH, CN, CF3, C1-4alkyl, C1-4alkoxy, amino, C1-4alkylamino and di(C1-4alkyl)amino;or two R8 groups attached to the same nitrogen atom may complete a heterocycle of up to 6 ring atoms which optionally bears up to 3 substituents independently selected from halogen, OH, oxo, CN, CF3, C1-4alkyl, C1-4alkoxy, amino, C1-4alkylamino and di(C1-4alkyl)amino.
    [0003] The process according to Claim 1 wherein RC is selected from the group consisting of:
    (i) hydrogen,
    (ii) halogen,
    (iii) OR7,
    (iv) N(R7)2,
    (v) CN,
    (vi) C1-8alkyl or C2-8alkenyl, either of which optionally bears up to 3 substituents independently selected from halogen, OH, CN, CF3, OR7, SR8, SO2R8, SO2N(R7)2, COR7, CO2R7, CON(R7)2, N(R7)2, NR7COR8 and NR7SO2R8; and
    (vii) C3-10cycloalkyl, C3-10cycloalkylC1-4alkyl, Het, HetC1-4alkyl, ARY or ARY-C1-4alkyl, any of which optionally bears up to 3 substituents independently selected from halogen, OH, oxo, CN, CF3, R8, OR7, SR8, SO2R8, SO2N(R7)2, COR7, CO2R7, CON(R7)2, N(R7)2, NR7COR8 and NR7SO2R8; where "ARY" refers to phenyl or 5- or 6-membered heteroaryl, either of which phenyl or heteroaryl is optionally fused to a 5- or 6-membered carbocycle or heterocycle, and "Het" refers to a nonaromatic mono- or bicyclic heterocyclic system of up to 10 ring atoms;R7 is H or C1-6alkyl which is optionally substituted with up to 3 halogen atoms or with OH, CN, CF3, C1-4alkoxy, amino, C1-4alkylamino or di(C1-4alkyl)amino, or R7 is phenyl, benzyl or 5- or 6-membered heteroaryl, any of which optionally bears up to 3 substituents independently selected from halogen, OH, CN, CF3, C1-4alkyl, C1-4alkoxy, amino, C1-4alkylamino and di(C1-4alkyl)amino;or two R7 groups attached to the same nitrogen atom may complete a heterocycle of up to 6 ring atoms which optionally bears up to 3 substituents independently selected from halogen, OH, oxo, CN, CF3, C1-4alkyl, C1-4alkoxy, amino, C1-4alkylamino and di(C1-4alkyl)amino; andR8 is C1-6alkyl which is optionally substituted with up to 3 halogen atoms or with OH, CN, CF3, C1-4alkoxy, amino, C1-4alkylamino or di(C1-4alkyl)amino, or R8 is phenyl, benzyl or 5- or 6-membered heteroaryl, any of which optionally bears up to 3 substituents independently selected from halogen, OH, CN, CF3, C1-4alkyl, C1-4alkoxy, amino, C1-4alkylamino and di(C1-4alkyl)amino;or two R8 groups attached to the same nitrogen atom may complete a heterocycle of up to 6 ring atoms which optionally bears up to 3 substituents independently selected from halogen, OH, oxo, CN, CF3, C1-4alkyl, C1-4alkoxy, amino, C1-4alkylamino and di(C1-4alkyl)amino.
    [0004] The process according to Claim 1 wherein PG is selected from the group consisting of: C1-6 alkyl, vinyl, C(O)-O-L, C(O)-L, aryl, heteroaryl, benzyl, benzhydryl, trityl and C1-6alkoxymethyl, wherein aryl, heteroaryl, benzyl, benzyhydryl and trityl optionally are substituted with 1 to 3 substituents independently selected from methoxy and nitro, C1-6alkoxymethyl is optionally substituted with trimethylsilyl and L is C1-6alkyl, aryl or benzyl.
    [0005] The process according to Claim 1 wherein W is selected from the group consisting of: halogen and sulfonate.
    [0006] The process according to Claim 1 wherein the water-immiscible organic phase is selected from the group consisting of benzene, toluene, xylenes, chlorobenzene, ethyl ether, isopropyl ether, tetrahydrofuran, 2-methyl tetrahydrofuran, dioxane, methyl tert-butyl ether, cyclopentyl methyl ether, isopropyl acetate, ethyl acetate, hexanes, heptanes, cyclohexane, dichloromethane and dichloroethane.
    [0007] The process according to Claim 1 wherein the base is selected from the group consisting of: sodium hydroxide, lithium hydroxide, potassium hydroxide, sodium carbonate, lithium carbonate, potassium carbonate, cesium hydroxide, cesium carbonate, sodium hydrogen carbonate, cesium hydrogen carbonate, potassium hydrogen carbonate, lithium hydrogen carbonate, lithium fluoride, sodium fluoride, potassium fluoride, cesium fluoride, lithium tert-butoxide, sodium tert-butoxide, potassium tert-butoxide, cesium tert-butoxide, sodium phosphate, lithium phosphate and potassium phosphate.
    [0008] The process according to Claim 1 wherein the water-immiscible organic phase is toluene and the base is sodium hydroxide.
    类似技术:
    公开号 | 公开日 | 专利标题
    JP6878615B2|2021-05-26|A novel heterocyclic derivative useful as an SHP2 inhibitor
    JP6434511B2|2018-12-05|Method for producing dihydropyrimidine derivatives and intermediates thereof
    AU2014318025B2|2020-02-06|Aryl ethers and uses thereof
    US9932343B2|2018-04-03|Fused tricyclic benzimidazoles derivatives as modulators of TNF activity
    DK2670752T3|2016-07-04|Pyrrolopyrazine spirocyclic piperidinamide as ion channel modulators
    EP2945938B1|2018-03-07|3-substituted pyrazoles and use as dlk inhibitors
    JP6484632B2|2019-03-13|Tetrahydroimidazopyridine derivatives as modulators of TNF activity
    CA2701292C|2015-03-24|Process for making thienopyrimidine compounds
    AP1164A|2003-06-30|Substituted 6,6-hetero-bicyclic derivatives.
    CA2262692C|2002-06-11|Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
    CA2296031C|2008-01-08|Novel spiroazabicyclic heterocyclic compounds
    KR101805914B1|2017-12-06|Substituted heterocycle fused gamma-carbolines synthesis
    AU735401B2|2001-07-05|Substituted 6,5-hetero-bicyclic derivatives
    US9890174B2|2018-02-13|Fused Tricyclic imidazole derivatives as modulators of TNF activity
    AU716376B2|2000-02-24|Substituted indazole derivatives and their use as phosphodiesterase | type IV and tumor necrosis factor | inhibitors
    JP4866722B2|2012-02-01|Fused N-heterocyclic compounds and their use as CRF receptor antagonists
    AU2012300248B2|2015-08-27|Compounds and compositions as c-kit kinase inhibitors
    ES2314690T3|2009-03-16|DERIVATIVES OF TRIAZOLOPIRIDINILSULFANILO AS INHIBITORS OF MAP QUINASA P38.
    CA2894298C|2017-04-18|Substituted dihydroisoquinolinone compounds
    EP2318377B1|2013-08-21|Pyrimidine compounds, compositions and methods of use
    KR20160145796A|2016-12-20|1H-PYRROLO[2,3-c]PYRIDIN-7|-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7|-ONES AS INHIBITORS OF BET PROTEINS
    US8138173B2|2012-03-20|Pyrazolo[3,4-C]quinolines, pyrazolo[3,4-C]naphthyridines, analogs thereof, and methods
    EP0730594B1|1999-09-08| 9-HYDROXY-PYRIDO [1,2-a]PYRIMIDIN-4-ONE ETHER DERIVATIVES
    RU2476430C2|2013-02-27|Aminodihydrothiazine derivatives substituted by cyclic group
    ES2250689T3|2006-04-16|1H-PIRIDO | THERAPEUTIC INDOLES.
    同族专利:
    公开号 | 公开日
    CN104144929A|2014-11-12|
    US9376431B2|2016-06-28|
    KR20200003243A|2020-01-08|
    AU2019206049B2|2021-04-01|
    KR102153850B1|2020-09-08|
    JP2015516945A|2015-06-18|
    EP2825536A1|2015-01-21|
    RU2014141166A|2016-05-10|
    JP6140266B2|2017-05-31|
    AU2017204464B2|2019-04-18|
    KR20140138704A|2014-12-04|
    AU2013232191B2|2017-03-30|
    US20150031891A1|2015-01-29|
    CN104144929B|2016-09-14|
    MX2014010999A|2014-10-13|
    EP2825536A4|2015-10-28|
    KR102061180B1|2019-12-31|
    AU2019206049A1|2019-08-01|
    AU2017204464A1|2017-07-20|
    CA2865941A1|2013-09-19|
    RU2667909C2|2018-09-25|
    BR112014021828B1|2019-04-24|
    MX351657B|2017-10-23|
    ES2806150T3|2021-02-16|
    EP2825536B1|2020-06-17|
    WO2013138413A1|2013-09-19|
    AU2013232191A1|2014-08-21|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    2020-06-12| PUAI| Public reference made under article 153(3) epc to a published international application that has entered the european phase|Free format text: ORIGINAL CODE: 0009012 |
    2020-06-12| STAA| Information on the status of an ep patent application or granted ep patent|Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED |
    2020-07-15| AX| Request for extension of the european patent|Extension state: BA ME |
    2020-07-15| AK| Designated contracting states|Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
    2020-07-15| AC| Divisional application: reference to earlier application|Ref document number: 2825536 Country of ref document: EP Kind code of ref document: P |
    2021-01-22| STAA| Information on the status of an ep patent application or granted ep patent|Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
    2021-02-24| RAX| Requested extension states of the european patent have changed|Extension state: BA Payment date: 20210115 Extension state: ME Payment date: 20210115 |
    2021-02-24| RBV| Designated contracting states (corrected)|Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
    2021-02-24| 17P| Request for examination filed|Effective date: 20210115 |
    2021-06-09| STAA| Information on the status of an ep patent application or granted ep patent|Free format text: STATUS: GRANT OF PATENT IS INTENDED |
    2021-06-09| GRAP| Despatch of communication of intention to grant a patent|Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
    2021-07-07| INTG| Intention to grant announced|Effective date: 20210610 |
    2022-01-31| STAA| Information on the status of an ep patent application or granted ep patent|Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
    2022-01-31| GRAJ| Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted|Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
    优先权:
    申请号 | 申请日 | 专利标题
    [返回顶部]